• Genesys Diagonists launches
    COVID-19 testing
    with Respiratory Viral Panel

  • A new era of
    genetic
    testing

  • Oncology

  • Pharmacogenetics

  • Prenatal

  • Neurology

  • Infectious Diseases

  • Pharma services / Companion Diagnostics

Press Release

Genesys Diagnostics Inc. Launches COVID-19 testing along with Respiratory Viral Pathogen Panel.

In response to the rapidly evolving situation with the novel coronavirus disease (COVID-19), Genesys Diagnostics Inc., is implementing a high-throughput, more comprehensive option, with the NxTAG® CoV Extended Panel, which can detect three recent coronavirus targets: CoVID-19 (ORF, E-gene, and N-gene). This panel will be run in parallel with the NxTAG® Respiratory Pathogen Panel (RPP) with Influenza and 18 other viruses and bacteria to provide a more complete picture of a patient’s respiratory health. Genesys Diagnostics came Live with COVID-19 testing on March 17, 2019. Genesys Diagnostics can test 500 samples a day and is planning to increase the capacity to 1000 samples a day.

The NaTAG CoV 2019 Novel Coronavirus (COVID-19), has been validated by Genesys Diagnostics internally and is being made available pursuant to guidance issued by the U.S. Food and Drug Administration (FDA). Genesys Diagnostics test has been validated for use with respiratory samples, including nasopharyngeal (NP) swabs.

We are proud to state that Genesys Diagnostics Inc., is the first lab located in the state of Connecticut & New England to launch the COVID-19 test. Genesys Diagnostics is serving local hospitals in Connecticut and Massachusetts. We look forward to serving our communities with the highest quality of service and fastest turnaround times.

Services We Provide

Oncology

More

Pharmacogenetics

More

Prenatal

More

Neurology

More

Infectious Diseases

More

PHARMA Services / Companion Diagnostics

More